Características morfofisiológicas em plantas de Tabebuia heptaphyilla (vell.) tol. em condições de luminosidade Morphophysiological characteristics in plants of Tabebuia heptaphyilla (vell.) tol., in conditions of luminosity

Um fator importante na determinação da sobrevivência de uma espécie, é sua adaptação à condição de alta ou baixa luminosidade. O objetivo deste estudo foi verificar o desenvolvimento inicial, teores de clorofila e alocação de biomassa em plantas de Tabebuia heptaphyilla (Vell.) Tol, em três condições de luminosidade. O experimento foi conduzido em delineamento de blocos casualizados, com três níveis de luminosidade (pleno sol, 50% de luz e sombra natural) e com 15 repetições em cada tratamento, sendo cada planta considerada como uma repetição. Foram avaliados a altura e diâmetro aos 60, 82, 103, 124, 145 dias após a emergência das plântulas. Plantas expostas ao ambiente de sombra natural apresentaram menor desempenho vegetativo do que as demais condições de cultivo testadas (50% e 100% de luminosidade). A condição de 50% de luminosidade pode ser recomendada para a formação de mudas, no entanto, essa prática também pode ser realizada a pleno sol.<br>Important factor in determining species survival, for example, its adaptability to high or low conditions of luminosity. The objective of this study was to verify the initial development, chlorophyll content, and biomass allocation in plants of Tabebuia heptaphyilla (vell.) tol., in three lighting conditions. The experiment was carried out in randomized complete blocks, with three levels of luminosity (full sunlight, 50% of light, and natural shade) and 15 repetitions of each treatment, and each plant considered as a repetition. The height and diameter were studied on 60, 82, 103, 124, 145 days after the emergence of the plants. Plants exposed in the shade showed lower vegetation performance than the other conditions tested (50% and 100% of RFA). The 50% luminosity, as well as full sunlight, can be recommended for the formation of seedlings

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)